Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the HERG Screening Sector?

In recent times, rapid expansion has been witnessed in the HERG screening market size. Its growth is projected to escalate from a robust $1.62 billion in 2024 to a whopping $1.84 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. The exponential growth during the historic period is linked to factors such as an upsurge in drug development activities, stringent regulatory protocols, heightened awareness regarding cardiac health, and a surge in the occurrence of cardiac disorders.

In the coming years, a swift expansion is anticipated in the HERG screening market, which is projected to reach “ $2.88 billion by 2029, with a compound annual growth rate (CAGR) of 11.9%.” Factors contributing to this growth during the projected period include the development of personalized medicine, the trend of outsourcing drug development initiatives, the growth of emerging markets and research, as well as emphasis on non-cardiac safety evaluation. Key trends predicted to impact this period are improvements in in vitro models, the merging of genomic and proteomic data, advancements in computational methodologies, a heightened focus on pediatric drug safety, and cooperative efforts for data sharing and standardization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Forces Are Driving The Growth Of The HERG Screening Market?

The increase in heart disorder patients is set to push forward the expansion of the HERG screening market. Heart disorders, also recognized as cardiovascular diseases, are a variety of conditions that can harm the heart and blood vessels, compromising the heart’s capacity to function correctly and potentially leading to severe health issues. Factors such as unhealthy lifestyles, an aging population, genetic predisposition, diabetes, and metabolic syndrome can give rise to these disorders. HERG screening enables the discovery of potential drug prospects, prevention of cardiac incidents that could cause fatal cardiac arrhythmias, especially torsade de pointes (TdP), and enhancement of patient results. For example, a May 2023 report by the US-based Centers for Disease Control and Prevention revealed that 1 in 20 adults aged 20 and above were afflicted with cardiovascular diseases, with 695,000 persons living with these diseases and 375,476 persons dying from them. Moreover, a report from the UK-based Office for National Statistics published in March 2022 stated that 20,061 individuals died from heart attacks, indicating an increase from the previous year. As such, the surge in heart disorder patients is contributing to the escalation of the HERG screening market.

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

How Are Key Trends Driving Expansion In The HERG Screening Industry?

Leading organisations in the HERG screening market are focusing on developing novel advanced solutions like GLP-certified HERG screening services to improve cardiac safety evaluations in drug development procedures. These services involve good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) using the standard whole-cell patch-clamp method. This ensures that the service complies with necessary standards such as ICH S7A and ICH S7B, which are vital for safety pharmacology research during drug creation. In August 2023, Metrion Biosciences Ltd., a pharmaceutical firm based in the UK, debuted its GLP-certified hERG screening service. The intention is to boost Metrion’s assistance for the evolution of small-molecule therapeutics and augment their current cardiac safety services. Moreover, this service uses the whole-cell patch-clamp methodology to examine possible cardiac risks before beginning Phase 1 of human clinical trials. It offers guidance on regulations for safety pharmacology studies in drug creation and presents customers with high-grade biology utilities for ion channel targets.

Which Companies Currently Dominate The Competitive Landscape In The HERG Screening Industry?

Major companies operating in the HERG screening market are Eurofins-Cerep SA., Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., Crprotex Limited, ChanTest Corporation, Creative bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ABR-Affinity BioReagents Inc., ACEA Biosciences Inc., Metrion biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, B’SYS GmbH, Cambridge Bioscience Ltd., Sophion Bioscience Inc., Fluxion Biosciences Inc., ChemAxon Ltd.

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Which Geographic Regions Are Driving Demand In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2024. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the HERG screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14392&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model